Quarterly report pursuant to Section 13 or 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)

v3.23.3
Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Balance $ 1,966,516  
Other comprehensive income (loss), before tax:    
Balance 1,997,746  
Unrealized Gains (Losses) on Derivative Instruments    
Balance 12,862 $ 8,069
Other comprehensive income (loss), before tax:    
Amounts before reclassifications, attributable to Bio-Techne 1,587 4,376
Amounts reclassified out (2,539) 417
Total other comprehensive income (loss), before tax (952) 4,793
Tax (expense)/benefit (602) 98
Total other comprehensive income (loss), net of tax (350) 4,695
Balance 12,512 12,764
Foreign Currency Translation Adjustments    
Balance (78,926) (83,269)
Other comprehensive income (loss), before tax:    
Amounts before reclassifications, attributable to Bio-Techne (11,069) (21,457)
Amounts reclassified out (698) 152
Total other comprehensive income (loss), before tax (11,767) (21,305)
Tax (expense)/benefit (165) 0
Total other comprehensive income (loss), net of tax (11,602) (21,305)
Balance (90,528) (104,574)
Accumulated Other Comprehensive Income    
Balance (66,064) (75,200)
Other comprehensive income (loss), before tax:    
Amounts before reclassifications, attributable to Bio-Techne (9,482) (17,081)
Amounts reclassified out (3,237) 569
Total other comprehensive income (loss), before tax (12,719) (16,512)
Tax (expense)/benefit (767) 98
Total other comprehensive income (loss), net of tax (11,952) (16,610)
Balance $ (78,016) $ (91,810)